KOL Insight - Haemophilia A

This report offers a detailed analysis of the haemophilia A treatment landscape, highlighting both current therapies and innovative pipeline products. Insights from leading key opinion leaders assess the efficacy, tolerability, and administration of prominent treatments like Hemlibra and Altuviiio. This report also explores the transformative potential of emerging gene therapies and bispecific antibodies. Gain a comprehensive understanding of the factors influencing treatment preferences, the challenges new therapies face, and the evolving treatment algorithms.

Key Questions Answered:

• 1. What are the preferred first-line and subsequent-line treatments for haemophilia A, and why?
• 2. How do current haemophilia A treatments compare in terms of efficacy, tolerability, and ease of administration?
• 3. What must pipeline therapies demonstrate to become the treatment of choice in haemophilia A?
• 4. How is the use of current and pipeline haemophilia A products expected to change in the future?
• 5. What efficacy and tolerability endpoints must pipeline products achieve to compete effectively?
• 6. Which pipeline products are most promising, and how will they impact current market players?

Key Brands:

Partial List of Participating Experts:

• Consultant Haematologist, Haemophilia Centre Director, St Thomas' Comprehensive Care Centre, London, UK
• Professor of Hemostasis and Thrombosis, Division of Hematology and Medical Oncology, Mount Sinai Medical Center, New York, NY
• Professor of Medicine, Chef de Service - Service d'Hematologie chez Cliniques Universitaires Saint-Luc, Brussels, Belgium
• Professor of Medicine, Director of Haematology at a teaching hospital, Sweden
• Professor of Pediatrics and Pathology, Pediatric Medical Director, Hemophilia and Coagulation Disorders Program, University of Michigan, Ann Arbor, MI
• Professor of Pediatrics, Director, Hemostasis and Thrombosis Program, Keck School of Medicine of USC, Los Angeles, CA

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.